{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:28Z","timestamp":1790188168010,"version":"4.1.0"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pancreatic Cancer (PC) is one of the most malignant tumors and highly invasive\nneoplasms around the world.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This systematic review and meta-analysis aims to study the relationship between the use\nof renin-angiotensin-aldosterone system inhibitors and the incidence and mortality of PC.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The electronic search was conducted systematically until October 10, 2023. in databases,\nincluding Scopus, Web of Science (WOS), PubMed\/MEDLINE, Cochrane Library, and Embase.\nThe required data were extracted from the articles and were analyzed by Stata 15 using statistical\ntests (Chi-square and I2), Forest plots, and publication bias tests (Begg's and Egger's tests).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of four studies (2011-2019; n=314,856) investigated the relationship between RAS\nantagonists and PC risk. No significant associations were found between angiotensin receptor\nblockers (ARBs) (OR=0.94, 95% CI: 0.77-1.14, p=0.513), angiotensin-converting enzyme inhibitors\n(ACEIs) (OR=0.96, 95% CI: 0.84-1.09, p=0.505), or combination therapy (ARBs + ACEIs)\n(OR=0.97, 95% CI: 0.87-1.09, p=0.627) and PC risk. Also, nine studies (2010-2023; n=20,483) examined\nthe association between renin-angiotensin-aldosterone system inhibitors and PC mortality.\nSignificant reductions in PC mortality were found for ARBs (OR=0.81, 95% CI: 0.66-0.98,\np=0.032), ACEIs (OR=0.89, 95% CI: 0.80-0.99, p=0.038), and combination therapy (OR=0.83,\n95% CI: 0.70-0.97, p=0.022). No evidence of publication bias was found in the study results.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In summary, while renin-angiotensin-aldosterone system inhibitors did not appear to\nimpact PC risk, their use was associated with lower PC mortality based on this meta-analysis of the\ncurrent evidence. More rigorous and well-designed studies are required to validate and support these\nfindings.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0127724328291047240409062436","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T09:48:12Z","timestamp":1713347292000},"page":"60-71","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Association between use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2176-6035","authenticated-orcid":true,"given":"Rasoul","family":"Rahimi","sequence":"first","affiliation":[{"name":"Department of Surgery, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2379-9628","authenticated-orcid":true,"given":"Seyed Mahmood Reza","family":"Hashemi Rafsanjani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tehran\nMedical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-3868","authenticated-orcid":true,"given":"Saeid","family":"Heidari-Soureshjani","sequence":"additional","affiliation":[{"name":"Modeling in Health Research Center, Shahrekord University\nof Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-3207","authenticated-orcid":true,"given":"Catherine Mary Turner","family":"Sherwin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Clinical Pharmacology and Toxicology,\nWright State University Boonshoft School of Medicine, Dayton Children's Hospital, One Children's Plaza, Dayton,\nOhio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamali","family":"Kasiri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"Rawla P.","year":"2019","unstructured":"Rawla P.; Sunkara T.; Gaduputi V.; Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol  2019,10(1),10-27","journal-title":"World J Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1533033820962117","author":"Zhao Z.","year":"2020","unstructured":"Zhao Z.; Liu W.; Pancreatic cancer: A review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat  2020,19","journal-title":"Technol Cancer Res Treat"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"zrac174","DOI":"10.1093\/bjsopen\/zrac174","volume":"7","author":"Henry A.C.","year":"2023","unstructured":"Henry A.C.; van Dongen J.C.; van Goor I.W.J.M.; Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: Nationwide, observational cohort study. BJS Open  2023,7(2),zrac174","journal-title":"BJS Open"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e8188","DOI":"10.7717\/peerj.8188","volume":"7","author":"Wei J.","year":"2019","unstructured":"Wei J.; Zhou Z.; Xu Z.; Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension. PeerJ  2019,7,e8188","journal-title":"PeerJ"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.pan.2020.09.002","volume":"20","author":"Malangone-Monaco E.","year":"2020","unstructured":"Malangone-Monaco E.; Doleh Y.; Cole A.; Noxon V.; Antico G.; Pishvaian M.J.; The economic burden of metastatic pancreatic cancer. Pancreatology  2020,20(7),1434-1441","journal-title":"Pancreatology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3390\/cancers15061911","volume":"15","author":"Cipora E.","year":"2023","unstructured":"Cipora E.; Partyka O.; Pajewska M.; Treatment costs and social burden of pancreatic cancer. Cancers  2023,15(6),1911","journal-title":"Cancers"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e25496","DOI":"10.7759\/cureus.25496","volume":"14","author":"Miyaki C.","year":"2022","unstructured":"Miyaki C.; Lynch L.M.; An update on common pharmaceuticals in the prevention of pancreatic cancer. Cureus  2022,14(5),e25496","journal-title":"Cureus"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17474124.2022.2088506","volume":"16","author":"Jiang W.","year":"2022","unstructured":"Jiang W.; He R.; Lu Y.; Zhou W.; The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: A systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol  2022,16(6),547-553","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/20420986221129335","author":"Shin K.","year":"2022","unstructured":"Shin K.; Yang J.; Yu Y.; Son E.; Kim K.; Kim Y.H.; Angiotensin converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: An updated meta-analysis of observational studies. Ther Adv Drug Saf  2022,13","journal-title":"Ther Adv Drug Saf"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"CD009096","DOI":"10.1002\/14651858.CD009096.pub2","volume":"2014","author":"Li E.C.K.","year":"2014","unstructured":"Li E.C.K.; Heran B.S.; Wright J.M.; Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Libr  2014,2014(8),CD009096","journal-title":"Cochrane Libr"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e0242314","DOI":"10.1371\/journal.pone.0242314","volume":"15","author":"Her A.Y.","year":"2020","unstructured":"Her A.Y.; Choi B.G.; Rha S.W.; Kim Y.H.; Choi C.U.; Jeong M.H.; The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. PLoS One  2020,15(11),e0242314","journal-title":"PLoS One"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11886-020-01352-8","volume":"22","author":"Turner J.M.","year":"2020","unstructured":"Turner J.M.; Kodali R.; Should angiotensin-converting enzyme inhibitors ever be used for the management of hypertension? Curr Cardiol Rep  2020,22(9),95","journal-title":"Curr Cardiol Rep"},{"key":"ref=14","first-page":"205","volume":"45","author":"Timmermans P.B.","year":"1993","unstructured":"Timmermans P.B.; Wong P.C.; Chiu A.T.; Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev  1993,45(2),205-251","journal-title":"Pharmacol Rev"},{"key":"ref=15","first-page":"306","volume":"26","author":"Poredos P.","year":"2007","unstructured":"Poredos P.; Jezovnik M.K.; The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol  2007,26(4),306-311","journal-title":"Int Angiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00432-020-03445-x","volume":"147","author":"Rachow T.","year":"2021","unstructured":"Rachow T.; Schiffl H.; Lang S.M.; Risk of lung cancer and renin\u2013angiotensin blockade: A concise review. J Cancer Res Clin Oncol  2021,147(1),195-204","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jch.14187","volume":"23","author":"Jung M.H.","year":"2021","unstructured":"Jung M.H.; Lee J.H.; Lee C.J.; Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea. J Clin Hypertens  2021,23(4),879-887","journal-title":"J Clin Hypertens"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/diagnostics12020263","volume":"12","author":"Lee S.H.","year":"2022","unstructured":"Lee S.H.; Park J.; Park R.W.; Renin-angiotensin-aldosterone system inhibitors and risk of cancer: A population-based cohort study using a common data model. Diagnostics  2022,12(2),263","journal-title":"Diagnostics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.3892\/ol.2017.6826","volume":"14","author":"Sobczuk P.","year":"2017","unstructured":"Sobczuk P.; Szczylik C.; Porta C.; Czarnecka A.; Renin angiotensin system deregulation as renal cancer risk factor (Review). Oncol Lett  2017,14(5),5059-5068","journal-title":"Oncol Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-20-1401","volume":"30","author":"Brasky T.M.","year":"2021","unstructured":"Brasky T.M.; Flores K.F.; Larson J.C.; Associations of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with colorectal cancer risk in the women\u2019s health initiative. Cancer Epidemiol Biomarkers Prev  2021,30(5),1029-1032","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=21","first-page":"1","author":"Peterson J.","year":"2011","unstructured":"Peterson J.; Welch V.; Losos M.; Tugwell P.;  The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses  2011,1-12","journal-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1359-6349(06)80521-5","volume":"4","author":"Khurana V.","year":"2006","unstructured":"Khurana V.; Caldito G.; Barkin J.S.; Angiotensin converting enzyme inhibitors decrease the incidence of pancreatic cancer: A study of half a million US veterans. Eur J Cancer, Suppl  2006,4(1),47-48","journal-title":"Eur J Cancer, Suppl"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5414\/CP202842","volume":"55","author":"Fujimoto M.","year":"2017","unstructured":"Fujimoto M.; Kanou M.; Hosomi K.; Takada M.; Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database. Int J Clin Pharmacol Ther  2017,55(4),295-303","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2022.2007","DOI":"10.1101\/2022.07.26.22278092","author":"Tse G.","year":"2022","unstructured":"Tse G.; Zhou J.; Lee S.; Incidence of pancreatic cancer in angiotensin-converting enzyme inhibitors (ACEIs) versus angiotensin receptor blockers (ARBs): A population-based cohort study. medRxiv  2022,2022.2007","journal-title":"medRxiv"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3346\/jkms.2011.26.1.59","volume":"26","author":"Chin H.J.","year":"2011","unstructured":"Chin H.J.; Oh S.W.; Goo H.S.; Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci  2011,26(1),59-66","journal-title":"J Korean Med Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/bjc.2016.375","volume":"116","author":"Mandilaras V.","year":"2017","unstructured":"Mandilaras V.; Bouganim N.; Yin H.; Asselah J.; Azoulay L.; The use of drugs acting on the renin\u2013angiotensin system and the incidence of pancreatic cancer. Br J Cancer  2017,116(1),103-108","journal-title":"Br J Cancer"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/jcm7080197","volume":"7","author":"Wang Z.","year":"2018","unstructured":"Wang Z.; White D.; Hoogeveen R.; anti-hypertensive medication use, soluble receptor for glycation end products and risk of pancreatic cancer in the women\u2019s health initiative study. J Clin Med  2018,7(8),197","journal-title":"J Clin Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41416-019-0562-y","volume":"121","author":"Kirkeg\u00e5rd J.","year":"2019","unstructured":"Kirkeg\u00e5rd J.; Mortensen F.V.; Cronin-Fenton D.; Antihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: A Danish nationwide population-based cohort study. Br J Cancer  2019,121(7),622-624","journal-title":"Br J Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","volume":"103","author":"Nakai Y.","year":"2010","unstructured":"Nakai Y.; Isayama H.; Ijichi H.; Inhibition of renin\u2013angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer  2010,103(11),1644-1648","journal-title":"Br J Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/MPA.0b013e31825de678","volume":"42","author":"Nakai Y.","year":"2013","unstructured":"Nakai Y.; Isayama H.; Sasaki T.; Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: Better prognosis with statin use in diabetic patients. Pancreas  2013,42(2),202-208","journal-title":"Pancreas"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4291\/wjgp.v6.i4.235","volume":"6","author":"Tingle S.J.","year":"2015","unstructured":"Tingle S.J.; Moir J.A.; White S.A.; Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol  2015,6(4),235-242","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s00268-017-4021-8","volume":"41","author":"Cerullo M.","year":"2017","unstructured":"Cerullo M.; Gani F.; Chen S.Y.; Canner J.K.; Pawlik T.M.; Impact of angiotensin receptor blocker use on overall survival among patients undergoing resection for pancreatic cancer. World J Surg  2017,41(9),2361-2370","journal-title":"World J Surg"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e13219","DOI":"10.1111\/ecc.13219","volume":"29","author":"Bagni K.","year":"2020","unstructured":"Bagni K.; Chen I.M.; Johansen A.Z.; Prognostic impact of charlson\u2019s age\u2010comorbidity index and other risk factors in patients with pancreatic cancer. Eur J Cancer Care  2020,29(3),e13219","journal-title":"Eur J Cancer Care"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/0284186X.2021.1953136","volume":"60","author":"St\u00f8er N.C.","year":"2021","unstructured":"St\u00f8er N.C.; Bouche G.; Pantziarka P.; Sloan E.K.; Andreassen B.K.; Botteri E.; Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: A nationwide registry-based study in Norway. Acta Oncol  2021,60(9),1146-1153","journal-title":"Acta Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12885-022-09200-4","volume":"22","author":"Keith S.W.","year":"2022","unstructured":"Keith S.W.; Maio V.; Arafat H.A.; Angiotensin blockade therapy and survival in pancreatic cancer: A population study. BMC Cancer  2022,22(1),150","journal-title":"BMC Cancer"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/bjs\/znac434","volume":"110","author":"H\u00fcttner F.J.","year":"2023","unstructured":"H\u00fcttner F.J.; Mauch M.; Heckler M.; Influence of beta-blockers and other non-cancer drugs on outcomes after pancreatic cancer resection. Br J Surg  2023,110(4),498-499","journal-title":"Br J Surg"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"E1073","DOI":"10.1503\/cmaj.101497","volume":"183","author":"Yoon C.","year":"2011","unstructured":"Yoon C.; Yang H.S.; Jeon I.; Chang Y.; Park S.M.; Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: A meta-analysis of observational studies. CMAJ  2011,183(14),E1073-E1084","journal-title":"CMAJ"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","volume":"108","author":"Sipahi I.","year":"2011","unstructured":"Sipahi I.; Chou J.; Mishra P.; Debanne S.M.; Simon D.I.; Fang J.C.; Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol  2011,108(2),294-301","journal-title":"Am J Cardiol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1198952","DOI":"10.3389\/fimmu.2023.1198952","volume":"14","author":"Yao M.","year":"2023","unstructured":"Yao M.; Ma J.; Wu D.; Neutrophil extracellular traps mediate deep vein thrombosis: from mechanism to therapy. Front Immunol  2023,14,1198952","journal-title":"Front Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"6765","DOI":"10.18632\/oncotarget.6837","volume":"7","author":"Mao Y.","year":"2016","unstructured":"Mao Y.; Xu X.; Wang X.; Zheng X.; Xie L.; Is angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy protective against prostate cancer? Oncotarget  2016,7(6),6765-6773","journal-title":"Oncotarget"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","volume":"23","author":"Mc Menamin \u00da.C.","year":"2012","unstructured":"Mc Menamin \u00da.C.; Murray L.J.; Cantwell M.M.; Hughes C.M.; Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: A systematic review. Canc Cau Cont  2012,23(2),221-230","journal-title":"Canc Cau Cont"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","volume":"26","author":"Song T.","year":"2017","unstructured":"Song T.; Choi C.H.; Kim M.K.; Kim M.L.; Yun B.S.; Seong S.J.; The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. Eur J Cancer Prev  2017,26(1),78-85","journal-title":"Eur J Cancer Prev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"McGuigan A.","year":"2018","unstructured":"McGuigan A.; Kelly P.; Turkington R.C.; Jones C.; Coleman H.G.; McCain R.S.; Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol  2018,24(43),4846-4861","journal-title":"World J Gastroenterol"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316656679","volume":"17","author":"Shen J.","year":"2016","unstructured":"Shen J.; Huang Y.M.; Wang M.; Renin\u2013angiotensin system blockade for the risk of cancer and death. J Renin Angiot Aldost Syst  2016,17(3)","journal-title":"J Renin Angiot Aldost Syst"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.3390\/ijms24043814","volume":"24","author":"Nguyen N.T.H.","year":"2023","unstructured":"Nguyen N.T.H.; Nguyen P.A.; Huang C.W.; Renin-angiotensin-aldosterone system inhibitors and development of gynecologic cancers: A 23 million individual population-based study. Int J Mol Sci  2023,24(4),3814","journal-title":"Int J Mol Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e6394","DOI":"10.1097\/MD.0000000000006394","volume":"96","author":"Sun H.","year":"2017","unstructured":"Sun H.; Li T.; Zhuang R.; Cai W.; Zheng Y.; Do renin\u2013angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Medicine  2017,96(13),e6394","journal-title":"Medicine"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"736361","DOI":"10.3389\/fendo.2021.736361","volume":"12","author":"Almutlaq M.","year":"2021","unstructured":"Almutlaq M.; Alamro A.A.; Alamri H.S.; Alghamdi A.A.; Barhoumi T.; The effect of local renin angiotensin system in the common types of cancer. Front Endocrinol  2021,12,736361","journal-title":"Front Endocrinol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"Pinter M.","year":"2017","unstructured":"Pinter M.; Jain R.K.; Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med  2017,9(410),eaan5616","journal-title":"Sci Transl Med"},{"key":"ref=49","first-page":"884","volume":"11","author":"Yang J.","year":"2021","unstructured":"Yang J.; Yang X.; Gao L.; Zhang J.; Yi C.; Huang Y.; The role of the renin-angiotensin system inhibitors in malignancy: A review. Am J Cancer Res  2021,11(3),884-897","journal-title":"Am J Cancer Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","volume":"24","author":"Pinter M.","year":"2018","unstructured":"Pinter M.; Kwanten W.J.; Jain R.K.; Renin\u2013angiotensin system inhibitors to mitigate cancer treatment\u2013related adverse events. Clin Cancer Res  2018,24(16),3803-3812","journal-title":"Clin Cancer Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"djt374","DOI":"10.1093\/jnci\/djt374","volume":"106","author":"Makar G.A.","year":"2014","unstructured":"Makar G.A.; Holmes J.H.; Yang Y.X.; Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst  2014,106(2),djt374","journal-title":"J Natl Cancer Inst"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328291047240409062436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/228944\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328291047240409062436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T13:37:07Z","timestamp":1733751427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/228944\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328291047240409062436","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}